These include age, high blood pressure, smoking, diabetes, and a family history of heart disease

Wegovy (Semaglutide for Chronic Weight Management) FDA indication: Chronic weight management in adults with BMI 30 or greater, or BMI 27 or greater with at least one weight-related comorbidity Approved doses: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg (weekly subcutaneous injection) Target maintenance dose: 2.4 mg weekly Pediatric indication: Approved for adolescents aged 12 and older with obesity Ozempic (Semaglutide for Type 2 Diabetes) FDA indication: Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes Approved doses: 0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg (weekly subcutaneous injection) Note: Not FDA-approved for weight management, though frequently prescribed off-label Rybelsus (Oral Semaglutide) FDA indication: Type 2 diabetes management Doses: 3 mg, 7 mg, 14 mg (daily oral tablet) Lower bioavailability: Oral formulation has approximately 1% bioavailability, resulting in less predictable weight loss compared to injectable forms Comprehensive semaglutide training for physicians emphasizes the importance of prescribing the correct formulation for the correct indication

Pharmacies must balance supply across patients using these drugs for diabetes and those using them for weight loss, often under conditions where availability, while improved compared to earlier shortages, is still uneven at the local level
Los agonistas de GLP-1 incluyen semaglutida (Ozempic, Wegovy), liraglutida (Victoza, Saxenda) y dulaglutida (Trulicity)